Based on the promising results achieved during the First in Human Trial, today EpiTech officially launched its 2nd clinical trial, a 50 patient, multicenter, double masked, randomized controlled study.

This clinical trial is aligned with EpiTech’s regulatory strategy and targets subjects with severe aqueous deficient dry eye, and includes a 12-week follow-up period. Participating centers include Shaare Zedek Medical Center (Jerusalem), Ichilov Medical Center (Tel-Aviv) and Wolfson Medical Center (Holon).

Trial recruitment has already begun for all sites. If you suffer from Dry Eye Disease and wish to participate in this trial, please contact us.